Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04978272Phase 3Active Not Recruiting

Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP)

Role: lead

NCT04336189Phase 3Completed

Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda

Role: lead

NCT02163447Phase 3Completed

Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants

Role: lead

All 3 trials loaded